Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Broadcom Inc (AVGO) vs TransMedics Group Inc (TMDX) Price & Performance

Broadcom IncTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Broadcom Inc vs TransMedics Group Inc — how do they compare? Broadcom Inc trades at $393.65 (market cap $1.85T), while TransMedics Group Inc trades at $75 (market cap $2.58B). The key difference: Broadcom Inc is far larger — about 717.1× TransMedics Group Inc's market cap, and Broadcom Inc pays a 0.67% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

AVGOTMDX
Market Cap
$1.85T$2.58B
Sector
TechnologyTechnology
52-Week High
$481.57$150.42
52-Week Low
$278.59$61.99
Enterprise Value
$1.90T$2.98B
Dividend Yield
0.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Broadcom Inc

Broadcom (AVGO) trades at $384.05, down 3.98% on the day, but maintains strong fundamental momentum with consistent earnings beats and robust revenue growth. The stock shows bullish technical signals with support at $380 and resistance at $392, while fundamentals reveal impressive profitability with 38.85% net margins and 37.28% ROE. Recent analyst coverage remains overwhelmingly positive with 86% buy ratings.

AVGO presents a compelling growth story with AI-driven revenue expansion and strong cash flow generation, though elevated valuation multiples (P/E 63.9) and high debt levels warrant caution. The consensus price target of $509.70 suggests significant upside potential if execution continues, but investors should monitor competitive pressures in the semiconductor space.

TransMedics Group Inc

TransMedics (TMDX) trades at $75.74, up 6.33% today, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with support at $75 and resistance at $77. Recent strategic investments in European organ logistics through PAD Aviation position the company for international expansion, though margin pressure from these investments remains a concern. Analyst consensus remains strongly positive with a $108.71 price target.

The outlook remains favorable with 75% analyst buy ratings and significant upside potential from current levels. Key risks include execution challenges in European expansion, ongoing margin pressure from NOP investments, and competitive threats in the transplant logistics space. Revenue growth continues at 21% year-over-year, but investors should monitor margin trends and European rollout execution closely.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Broadcom Inc

Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.

Read more on AVGO

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX